Doug Fulling, MA, discussed how introducing payers into clinical research earlier could help manufacturers, payers, and patients.
Doug Fulling, MA, president of Precision AQ, spoke about the pros and cons of introducing payers into clinical research earlier, with emphasis on how it could benefit patients, payers, and manufacturers alike.
This transcript has been lightly edited.
Transcript
We're really excited about this conversation, because we feel that there's an opportunity to really change the blueprint for access. We know today that a majority of drugs that are launched fail to meet expectations from a launch perspective. And from a manufacturer perspective, that's disappointing because they're expecting certain financial results but there's also patients who are not getting those drugs, who could benefit from them. And so we believe by bringing payers into clinical research earlier, that we can create a better collaboration to enhance access to these new therapies that are being approved. Today, you've got more complex therapies, more expensive therapies. So if we can work closely with payers to come along on that evidence journey, as we're developing these, we think there'll be greater success in the marketplace from an access perspective. And at the end of the day, patients benefit from access.
So the pros are simply that if a payer gets pulled into the clinical development plan from the manufacturer, they have the ability to influence what that trial is going to look like, the end points that are going to be collected, and they can start to see that evidence being generated as the drug is actually being developed. And so for us, we think that that's a real benefit, because oftentimes, payers get pulled in once the drug has been approved, or shortly thereafter. And they're going to be looking for information to justify the expense of the drug, and to answer the benefits to their patient population, and how patients are going to benefit from the therapies. So by bringing them earlier on into the development, we feel like they'll be able to shape and design what clinical trials actually look like.
The cons could be that the product doesn't improve patients' lives that much and you could also be exposing some of the lack of evidence earlier on as well. But we believe that the pros definitely outweigh the cons and that you have that partner who's going to help you shape and design something that is going to eventually benefit their members.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More